Table 2 Univariate analysis of factors affecting the prognosis of patients with NMOSD

Age, years

43.40 ± 17.03

1.00 (0.99, 1.01)

0.834

0.99 (1.00, 1.01)

0.27

Male sex, no. (%)

93 (28.7%)

1.42 (0.87, 2.3)

0.159

1.36 (0.83, 2.23)

0.218

Hypertension, no. (%)

45 (13.9%)

0.39 (0.20, 0.75)

0.004

0.76 (0.40, 1.45)

0.411

Diabetes, no. (%)

19 (6%)

1.63 (0.60, 4.41)

0.344

0.63 (0.25, 1.59)

0.325

Initial EDSS

5 (3, 6)

1.13 (1.08, 1.36)

0.001

1.22 (1.08, 1.37)

0.001

Anti-AQP4 antibody, no. (%)

180 (66.4%)

0.68(0.41, 1.14)

0.146

0.96 (0.57, 1.61)

0.876

LETM

165 (75%)

0.76 (0.41, 1.42)

0.388

0.93 (0.50, 1.73)

0.811

Corticosteroids, no. (%)

310 (95.7%)

1.03 (0.35, 3.02)

0.965

0.46 (0.13, 1.67)

0.236

Immunoglobulins, no. (%)

33 (10.2%)

1.00 (0.48, 2.06)

0.986

1.18 (0.55, 2.53)

0.67

Immunosuppressants, no. (%)

111 (34.3%)

0.94 (0.59, 1.50)

0.801

0.99 (0.61, 1.59)

0.955

NLR

2.59 (1.63, 4.28)

1.28 (1.16, 1.41)

< 0.001

1.32 (1.20, 1.46)

< 0.001

PLR

131 (98, 199)

1.01 (1.00, 1.02)

< 0.001

1.01 (1.01, 1.02)

< 0.001

LMR

3.68 (2.56, 5.00)

1.01 (0.97, 1.06)

0.529

1.02 (0.98, 1.06)

0.458

DMT

45(13.9%)

1.12(0.59,2.13)

0.724

0.96 (1.50,1.83)

0.955